Frontier Biotechnologies’ HIV Drug Enters Phase I Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
Frontier Biotechnologies' anti-HIV type 1 Albuvirtide has entered Phase I clinical trials. The new patented drug developed by the Chinese firm shows strong inhibitory effects on HIV and its various index values appear better than other types of anti-HIV drugs on the market. Usage of imported products is at least RMB 80,000 ($11,712) per year, while popular domestic cocktail treatment costs more than RMB 4,000 annually and can lead to liver and kidney side effects. In contrast, Albuvirtide therapy has long-lasting effects of up to 20 days, translating to only one to two administrations per month and less than RMB 4,000 per year. (Click here for more - Chinese Language)